INTERVENTION 1:	Intervention	0
Arm A	Intervention	1
Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment	Intervention	2
day	UO:0000033	27-30
day	UO:0000033	67-70
day	UO:0000033	141-144
day	UO:0000033	193-196
day	UO:0000033	314-317
cyclophosphamide	CHEBI:4026	40-56
surgery	OAE:0000067	105-112
capecitabine	CHEBI:31348	152-164
x	LABO:0000148	125-126
x	LABO:0000148	188-189
Epirubicin: Epirubicin 90 mg/m2 d1 q3w	Intervention	3
Cyclophosphamide: Cyclophosphamide 600 mg/m2 d1 q3w	Intervention	4
cyclophosphamide	CHEBI:4026	0-16
cyclophosphamide	CHEBI:4026	18-34
Radiation Therapy: Standard dosing, fields depending on clinical findings	Intervention	5
INTERVENTION 2:	Intervention	6
Arm B	Intervention	7
Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment	Intervention	8
day	UO:0000033	29-32
day	UO:0000033	81-84
day	UO:0000033	149-152
day	UO:0000033	189-192
day	UO:0000033	314-317
capecitabine	CHEBI:31348	40-52
x	LABO:0000148	13-14
x	LABO:0000148	76-77
surgery	OAE:0000067	115-122
cyclophosphamide	CHEBI:4026	162-178
Docetaxel: Docetaxel 75 mg/m2 d1 q3w	Intervention	9
Capecitabine: Capecitabine 1000 mg/m2/dose bid x 14d q3w	Intervention	10
capecitabine	CHEBI:31348	0-12
capecitabine	CHEBI:31348	14-26
x	LABO:0000148	47-48
Radiation Therapy: Standard dosing, fields depending on clinical findings	Intervention	11
Inclusion Criteria:	Eligibility	0
Written informed consent	Eligibility	1
The diagnosis of breast cancer can be made by fine-needle aspiration (FNA), core, or tru-cut biopsy. Biopsy must demonstrate invasive adenocarcinoma.	Eligibility	2
breast cancer	DOID:1612	17-30
aspiration	HP:0002835	58-68
adenocarcinoma	DOID:299	134-148
Patients must have a life expectancy of at least 1 year, excluding their diagnosis of cancer.	Eligibility	3
year	UO:0000036	51-55
cancer	DOID:162	86-92
Patients must have a mass on clinical or radiological examination of >1 cm and must be confined to either the breast or to the breast and ipsilateral axilla. Multiple masses permitted, provided one of them is >1cm.	Eligibility	4
breast	UBERON:0000310	110-116
breast	UBERON:0000310	127-133
Patients may enter prior to ER or Her2 status being known, however if Her2 is positive, then the patient is withdrawn from the treatment phase of the trial.	Eligibility	5
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	97-104
Patients with palpable mass with distant metastasis and/or palpable supraclavicular lymphadenopathy allowed if definitive local treatment is judged to be necessary.	Eligibility	6
lymphadenopathy	HP:0002716	84-99
Patients may have inflammatory breast cancer.	Eligibility	7
breast cancer	DOID:1612	31-44
Prior to time of entry, patients must have had the following:	Eligibility	8
time	PATO:0000165	9-13
history and physical exam	Eligibility	9
history	BFO:0000182	0-7
blood tests	Eligibility	10
blood	UBERON:0000178	0-5
chest imaging within the last 3 months (chest x-ray, CT scan, PET/CT)	Eligibility	11
chest	UBERON:0001443	0-5
chest	UBERON:0001443	40-45
ct	BAO:0002125	53-55
ct	BAO:0002125	66-68
bilateral mammogram	Eligibility	12
bilateral	HP:0012832	0-9
Ultrasound of tumor with placement of clip to localize tumor should it respond completely to chemotherapy is recommended	Eligibility	13
Bone scan and MRI of the breast as clinically indicated.	Eligibility	14
breast	UBERON:0000310	25-31
Patients with clinically palpable lymph nodes are recommended to have a FNA biopsy to document the lymph node status. Patients may undergo a sentinel node biopsy procedure prior to preoperative chemotherapy.	Eligibility	15
lymph	UBERON:0002391	34-39
lymph	UBERON:0002391	99-104
document	IAO:0000310	86-94
At time of entry	Eligibility	16
time	PATO:0000165	3-7
White blood cell count (WBC) > 3,000	Eligibility	17
white blood cell count	CMO:0000027	0-22
platelet count > 100,000	Eligibility	18
platelet count	CMO:0000029	0-14
bilirubin, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate oxaloacetate transaminase (SGPT), alkaline phosphatase, and serum creatinine must all be < 1.2 x upper limit of normal (ULN)	Eligibility	19
glutamate	CHEBI:14321,BAO:0000926	17-26
glutamate	CHEBI:14321,BAO:0000926	69-78
phosphatase	GO:0016791,BAO:0000295	122-133
creatinine	CHEBI:16737	145-155
x	LABO:0000148	28-29
x	LABO:0000148	80-81
x	LABO:0000148	174-175
calculated creatinine clearance [Cockcroft-Gault] > 50 ml/min. normalized to a 1.73 m2 body surface area (BSA). Patients with benign hyperbilirubinemia are also excluded.	Eligibility	20
creatinine clearance	CMO:0000765	11-31
m2	CHEBI:34827	84-86
area	PATO:0001323	100-104
hyperbilirubinemia	HP:0002904,DOID:2741	133-151
excluded	HP:0040285	161-169
Patients with bone pain are eligible for inclusion if bone scan and/or roentgenological exam fail to disclose metastatic disease, or if metastatic disease is found, definitive local treatment is to be performed.	Eligibility	21
bone pain	HP:0002653	14-23
disease	DOID:4,OGMS:0000031	121-128
disease	DOID:4,OGMS:0000031	147-154
Patients with non-breast malignancies are eligible if they have not received prior chemotherapy, or extensive radiation therapy, and are free from disease for at least two years. Patients with squamous or basal carcinoma of the skin that has been effectively treated, carcinoma in situ of the cervix that has been treated by surgery only are eligible. Patients with prior or simultaneous lobular or ductal carcinoma in situ of the ipsilateral or contralateral breast are also eligible. Patients with bilateral breast cancer for which at least one of the breast cancers meet the eligibility requirements are also eligible.	Eligibility	22
disease	DOID:4,OGMS:0000031	147-154
carcinoma	HP:0030731,DOID:305	211-220
carcinoma	HP:0030731,DOID:305	268-277
carcinoma	HP:0030731,DOID:305	406-415
surgery	OAE:0000067	325-332
ductal carcinoma in situ	HP:0030075,DOID:0060074	399-423
breast	UBERON:0000310	18-24
breast	UBERON:0000310	460-466
breast	UBERON:0000310	510-516
breast	UBERON:0000310	554-560
bilateral breast cancer	DOID:6741	500-523
Has a negative serum or urine pregnancy test within 7 days prior to initiation of chemotherapy (female patients of childbearing potential).	Eligibility	23
urine	UBERON:0001088	24-29
female	PATO:0000383	96-102
Exclusion Criteria:	Eligibility	24
Patients with Her2 positive breast cancer	Eligibility	25
breast cancer	DOID:1612	28-41
Pregnancy or breast feeding at the time of proposed randomization. Women of childbearing potential with either a positive or no pregnancy test at baseline. Woman of childbearing potential not using a reliable and appropriate contraceptive method. (Postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential). Patients will agree to continue contraception for 30 days from the date of the last study drug administration.	Eligibility	26
breast	UBERON:0000310	13-19
time	PATO:0000165	35-39
drug administration	OAE:0000011	458-477
Participation in any investigational drug study within 4 weeks preceding the start of study treatment.	Eligibility	27
drug	CHEBI:23888	37-41
Prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.	Eligibility	28
severe	HP:0012828	20-26
5-fluorouracil	CHEBI:46345	89-103
Prior therapy for this breast cancer.	Eligibility	29
breast cancer	DOID:1612	23-36
Prior chemotherapy for a different breast cancer. Patients who have received prior anthracycline therapy for any malignancy are not eligible.	Eligibility	30
breast cancer	DOID:1612	35-48
anthracycline	CHEBI:48120	83-96
Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude the patient from being subjected to any of the treatment options or surgery or would prevent prolonged follow-up.	Eligibility	31
disease	DOID:4,OGMS:0000031	22-29
patient	HADO:0000008,OAE:0001817	93-100
surgery	OAE:0000067	157-164
prolonged	HP:0025297	182-191
Active cardiac disease that would preclude the use of epirubicin. This includes:	Eligibility	32
active	PATO:0002354	0-6
disease	DOID:4,OGMS:0000031	15-22
Any documented myocardial infarction or unstable angina;	Eligibility	33
myocardial infarction	HP:0001658,DOID:5844	15-36
Any history of documented congestive heart failure;	Eligibility	34
history	BFO:0000182	4-11
congestive heart failure	HP:0001635,DOID:6000	26-50
Valvular disease with documented cardiac function compromise;	Eligibility	35
disease	DOID:4,OGMS:0000031	9-16
function	BAO:0003117,BFO:0000034	41-49
Patients with cardiomegaly on chest X-ray, or ventricular hypertrophy on EKG, unless they demonstrate adequate left ventricular ejection fraction (LVEF) > 45% by MUltiple Gated Acquisition (MUGA) or echocardiogram.	Eligibility	36
cardiomegaly	HP:0001640	14-26
chest	UBERON:0001443	30-35
ventricular hypertrophy	HP:0001714	46-69
left	HP:0012835	111-115
ejection fraction	CMO:0000180	128-145
Patients with a cardiac arrhythmia are eligible, provided the arrhythmia is not associated with concomitant heart failure or cardiac dysfunction.	Eligibility	37
arrhythmia	HP:0011675	24-34
arrhythmia	HP:0011675	62-72
heart	UBERON:0000948	108-113
History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake.	Eligibility	38
history	BFO:0000182	0-7
central nervous system	UBERON:0001017	34-56
drug	CHEBI:23888	218-222
Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome.	Eligibility	39
malabsorption	HP:0002024	66-79
syndrome	DOID:225	80-88
Known, existing uncontrolled coagulopathy	Eligibility	40
Unwillingness to give written informed consent.	Eligibility	41
Unwillingness to participate or inability to comply with the protocol for the duration of the study.	Eligibility	42
duration	PATO:0001309	78-86
Outcome Measurement:	Results	0
Overall Response Rate	Results	1
rate	BAO:0080019	17-21
To describe the overall response rate as measured by physical exam and MRI if indicated using the following definition: Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.	Results	2
rate	BAO:0080019	33-37
target	BAO:0003064	192-198
target	BAO:0003064	253-259
target	BAO:0003064	345-351
diameter	PATO:0001334	333-341
Time frame: Up to 8 months	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Arm A	Results	5
Arm/Group Description: Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment	Results	6
day	UO:0000033	50-53
day	UO:0000033	90-93
day	UO:0000033	164-167
day	UO:0000033	216-219
day	UO:0000033	337-340
cyclophosphamide	CHEBI:4026	63-79
surgery	OAE:0000067	128-135
capecitabine	CHEBI:31348	175-187
x	LABO:0000148	148-149
x	LABO:0000148	211-212
Epirubicin: Epirubicin 90 mg/m2 d1 q3w	Results	7
Cyclophosphamide: Cyclophosphamide 600 mg/m2 d1 q3w	Results	8
cyclophosphamide	CHEBI:4026	0-16
cyclophosphamide	CHEBI:4026	18-34
Radiation Therapy: Standard dosing, fields depending on clinical findings	Results	9
Overall Number of Participants Analyzed: 37	Results	10
Measure Type: Count of Participants	Results	11
Unit of Measure: Participants  25  67.6%	Results	12
Results 2:	Results	13
Arm/Group Title: Arm B	Results	14
Arm/Group Description: Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment	Results	15
day	UO:0000033	52-55
day	UO:0000033	104-107
day	UO:0000033	172-175
day	UO:0000033	212-215
day	UO:0000033	337-340
capecitabine	CHEBI:31348	63-75
x	LABO:0000148	36-37
x	LABO:0000148	99-100
surgery	OAE:0000067	138-145
cyclophosphamide	CHEBI:4026	185-201
Docetaxel: Docetaxel 75 mg/m2 d1 q3w	Results	16
Capecitabine: Capecitabine 1000 mg/m2/dose bid x 14d q3w	Results	17
capecitabine	CHEBI:31348	0-12
capecitabine	CHEBI:31348	14-26
x	LABO:0000148	47-48
Radiation Therapy: Standard dosing, fields depending on clinical findings	Results	18
Overall Number of Participants Analyzed: 35	Results	19
Measure Type: Count of Participants	Results	20
Unit of Measure: Participants  21  60.0%	Results	21
Adverse Events 1:	Adverse Events	0
Total: 0/37 (0.00%)	Adverse Events	1
Adverse Events 2:	Adverse Events	2
Total: 0/35 (0.00%)	Adverse Events	3
